Epidemiology of Lung Cancer

Seminars in Roentgenology

Volumn 46, Issue 3, 2011, Pages 173-177

  McErlean, Aoife ^a   Ginsberg, Michelle S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; PROTEIN P53; RADON; RAS PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUTATOR GENE; ONCOGENE K RAS; PASSIVE SMOKING; PRIORITY JOURNAL; PROTEIN P53 GENE; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; SURVIVAL RATE; TOBACCO INDUSTRY; TREND STUDY; WOMEN'S HEALTH;

FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, RADIATION-INDUCED; PREVALENCE; RADON; RISK FACTORS; SMOKING; SURVIVAL RATE; TOBACCO SMOKE POLLUTION;

EID: 79959885152     PISSN: 0037198X     EISSN: 15584658     Source Type: Journal    
DOI: 10.1053/j.ro.2011.02.002     Document Type: Article

References (47)

1. Adler I. Primary Malignant Growths of the Lungs and Bronchi 1912, Longmans, Green, New York.
2. Rubin S.A. Lung cancer: Past, present, and future. J Thorac Imaging 1991, 7:1-8.
3. Harting F.H., Hesse W., et al. Der Lungenkrebs, die Bergenkrankheit in den Schneeberger Gruben. Vierteljahresschr Gerichtl Med 1879, 30:296-309.
4. Ochsener A., DeBakey M. Symposium on cancer: Primary pulmonary malignancy. Treatment by total pneumonectomy, analysis of 70 collected cases and presentation of 7 personal cases. Surg Gynecol Obstet 1939, 68:435-451.
5. Ferlay J., Shin H.R., Bray F., et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, [Internet]. Lyon, France: International Agency for Research on Cancer, Accessed February 16, 2011. http://globocan.iarc.fr.
6. Cancer Facts and Figures 2010 2010, American Cancer Society, American Cancer Society, Atlanta.
7. SEER Cancer Statistics Review 1975-2007, National Cancer Institute, Accessed February 16, 2011. http://seer.cancer.gov/csr/1975_2007/, S.F. Altekruse, C.L. Kosary, M. Krapcho (Eds.).
8. Racial/ethnic disparities and geographic differences in lung cancer incidence-38 states and the District of Columbia 1998-2006. Morb Mortal Wkly Rep 2010, 59:1434-1438. Centers for Disease Control.
9. Edwards B.K., Ward E., Kohler B.A., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
10. Klingerman S., White C. Epidemiology of lung cancer in women: Risk factors, survival and screening. AJR Am J Roentgenol 2011, 196:287-295.
11. Women and Smoking: A Report of the Surgeon General 2001, U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Washington, DC.
12. Risch H.A., Howe G.R., Jain M., et al. Are female smokers at higher risk for lung cancer than male smokers?. a case-control analysis by histologic type. Am J Epidemiol 1993, 38:281-293.
13. Zhang E.A., Wynder E.L. Differences in lung cancer risk between men and women: Examination of the evidence. J Natl Cancer Inst 1996, 88:183-192.
14. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 2006, 296:180-184. International Early Lung Cancer Action Program Investigators.
15. Kure E.H., Ryberg D., Hewer A., et al. p53 Mutations in lung tumours: Relationship to gender and lung DNA adduct levels. Carcinogenesis 1996, 17:2201-2205.
16. Patel J.D., Bach P.B., Kris M.G. Lung cancer in US women: a contemporary epidemic. JAMA 2004, 291:1763-1768.
17. Patel J.D. Lung cancer in women. J Clin Oncol 2005, 23:3212-3218.
18. Vineis P., Alavanja M., Buffler P., et al. Tobacco and cancer: Recent epidemiological evidence. J Natl Cancer Inst 2004, 96:99-106.
19. Hackshaw A.K., Law M.R., Wald N.J. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997, 315:980-988.
20. Stellman S.D., Muscat J.E., Thompson S., et al. Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. Cancer 1997, 80:382-388.
21. Devesa S.S., Shaw G.L., Blot W.J. Changing pattern of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev 1997, 1:29-34.
22. Patel A.R., Obrams G.I. Adenocarcinoma of the lung. Cancer Epidemiol Biomarkers Prev 1997, 4:175-180.
23. Harris J.E., Thun M.J., Mondul A.M., et al. Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8. BMJ 2004, 328:1-8.
24. Benowitz N.L. Compensatory smoking of low-yield cigarettes. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine 2001, 39-64. National Institutes of Health, National Cancer Institute, Bethesda, MD, (NCI Smoking and Tobacco Control Monograph No 13). D.R. Shopland, D.M. Burns, N.L. Benowitz (Eds.).
25. Pawel D.J., Puskin J.S. The U.S. Environmental Protection Agency's assessment of risks from indoor radon. Health Phys 2004, 87:68-74.
26. Pershagen G., Akerblom G., Axelson O., et al. Residential radon exposure and lung cancer in Sweden. N Engl J Med 1994, 330:159-164.
27. Schoenberg J.B., Klotz J.B., Wilcox H.B., et al. Case-control study of residential radon and lung cancer among New Jersey women. Cancer Res 1990, 50:6520-6524.
28. Barros-Dios J.M., Barreiro M.A., Ruano-Ravina A., et al. Exposure to Residential radon and Lung Cancer in Spain: a population-based Case-Control Study. Am J Epidemiol 2002, 156:548-555.
29. Environmental Tobacco Smoke: Measuring Exposures and Assessing Health Effects 1986, National Research Council, National Academies Press, Washington, DC.
30. The Health Consequences of Involuntary Smoking: a Report of the Surgeon General 1986, U.S. Department of Health and Human Services, DHHS, Washington, DC, (Publication No [PHS] 87-8398).
31. Hecht S.S., Carmella S.G., Murphy S.E. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 1993, 329:1543-1546.
32. Doll R., Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981, 66:1191-1308.
33. Neuberger J.S., Field R.W. Occupation and lung cancer in nonsmokers. Rev Environ Health 2003, 18:251-267.
34. Johnson B.E. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998, 90:1335-1345.
35. Engels E.A., Biggar R.J., Hall H.I., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187-194.
36. Chaturvedi A.K., Pfeiffer R.M., Chang L., et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007, 21:207-213.
37. D'Jaen G.A., Pantanowitz L., Bower M., et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010, 11:396-404.
38. Ford M.B., Sigurdson A.J., Petrulis E.S., et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 2003, 98:1457-1464.
39. Deutsch M., Land S.R., Begovic M., et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 2003, 98:1362-1368.
40. Cigarette use among high school students-United States, 1991-2009. Morb Mortal Wkly Rep 2010, 59:797-801. Centers for Disease Control.
41. Vital signs: current cigarette smoking among adults aged 18 years-United States 2009. Morb Mortal Wkly Rep 2010, 59:1135-1140. CDC.
42. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
43. Costa D.B., Kobayashi S., Tenen D.G., et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007, 58:95-103.
44. Riely G., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:201-209.
45. Marchetti A., Martella C., Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
46. Shigematsu H., Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2008, 118:257-262.
47. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.